checkAd

    Prana Biotech: PBT-2 - 500 Beiträge pro Seite (Seite 2)

    eröffnet am 05.08.03 19:55:17 von
    neuester Beitrag 08.07.21 22:28:15 von
    Beiträge: 531
    ID: 761.658
    Aufrufe heute: 0
    Gesamt: 48.831
    Aktive User: 0


     Durchsuchen
    • 2

    Begriffe und/oder Benutzer

     

    Top-Postings

     Ja Nein
      Avatar
      schrieb am 16.03.14 13:24:22
      Beitrag Nr. 501 ()
      Kaum zu glauben:

      Fidelity bought 1m Prana shares

      http://data.cnbc.com/quotes/PRAN/tab/8

      Wikipedia: Fidelity Investments
      "Die FMR LLC (Fidelity Investments), häufig kurz Fidelity, ist ein US-amerikanisches Unternehmen der Finanzdienstleistungsbranche mit Stammsitz in Boston, Massachusetts. Das Unternehmen ist einer der größten Vermögensverwalter der Welt..."
      1 Antwort
      Avatar
      schrieb am 16.03.14 14:57:11
      Beitrag Nr. 502 ()
      Und auch nicht zu vergessen:

      PRAN wird in Kürze in den ASX 300 aufgenommen:


      Prana Biotechnology (PRAN) is set to join the S&P/ASX 300 Index on March 21 following a quarterly review by Dow Jones.

      The S&P/ASX 300 is adjusted every quarter to reflect Australia's largest 300 companies by market cap. Dow Jone's decision comes after Prana's valuation surged to over $415M.
      Entrance to the S&P/ASX 300 will expose Prana to a wider range of investors.
      Avatar
      schrieb am 16.03.14 16:12:38
      Beitrag Nr. 503 ()
      Antwort auf Beitrag Nr.: 46.638.809 von Finee am 16.03.14 13:24:22confirmed:

      https://eresearch.fidelity.com/eresearch/evaluate/fundamenta…
      Avatar
      schrieb am 17.03.14 08:54:08
      Beitrag Nr. 504 ()
      YAHOO Prana Biotechnology Limited Message Board


      superpisboy • 4 hours ago

      Fidelity The biggest Mutual Fund Holder in Prana and ICPT
      Fidelity has almost the same amount of shares in PRana as it does in ICPT, and in my opinion the Prana investment could surpass ICPT.

      Who Wins With Intercept?
      By Brendan Conway
      "The remarkable surge in Intercept Pharmaceuticals’ (ICPT) stock — 582% this year, at last check — appears to have delivered handy gains to some well-known Fidelity Investments mutual funds. But it may have just missed one of the firm’s most famous funds.
      The big winner appears to be Fidelity Select Biotechnology (FBIOX). This mutual fund owned a little over 1.31 million shares as of the end of November, a position valued at $68.9 million... "
      1 Antwort
      Avatar
      schrieb am 17.03.14 09:01:01
      Beitrag Nr. 505 ()
      Antwort auf Beitrag Nr.: 46.641.841 von Finee am 17.03.14 08:54:08

      Trading Spotlight

      Anzeige
      Rallye II. – Neuer Anstoß, News und was die Börsencommunity jetzt nicht verpassen will…mehr zur Aktie »
      Avatar
      schrieb am 17.03.14 21:12:13
      Beitrag Nr. 506 ()
      beeindruckend

      heute morgen noch nachgelegt, und nun fast auf Tageshoch
      Avatar
      schrieb am 20.03.14 21:48:33
      Beitrag Nr. 507 ()
      Prana Biotechnology - A Gamble Worth Taking For Both Long- And Short-Term Investors

      March 20, 2014


      http://seekingalpha.com/article/2100583-prana-biotechnology-…
      Avatar
      schrieb am 21.03.14 09:33:47
      Beitrag Nr. 508 ()
      Gigantisches PRAN Handelsvolumen an der ASX am heutigen Freitag (ASX nun geschlossen, Australien ist bekanntlich unserer Uhrzeit voraus).
      Avatar
      schrieb am 21.03.14 11:08:22
      Beitrag Nr. 509 ()
      Zitat von Fruehrentner: Gigantisches PRAN Handelsvolumen an der ASX am heutigen Freitag (ASX nun geschlossen, Australien ist bekanntlich unserer Uhrzeit voraus).


      Bei mir zeigt es die letzten 2 Tage dasselbe Handelsvolumen an.
      Oder liege ich falsch

      Grüße
      3 Antworten
      Avatar
      schrieb am 21.03.14 11:29:46
      Beitrag Nr. 510 ()
      Avatar
      schrieb am 21.03.14 12:58:43
      Beitrag Nr. 511 ()
      Antwort auf Beitrag Nr.: 46.672.745 von muellerei am 21.03.14 11:08:22PBT - PRANA BIOTECHNOLOGY LIMITED
      Course of Sales 21.03.2014
      Time (AEST) Price Volume Value
      18:47:01 1.239 416,552 516,107.93
      18:46:50 1.239 41,964 51,993.40
      18:46:35 1.239 115,545 143,160.26
      18:34:15 1.239 998,592 1,237,255.49
      18:04:30 1.240 294,210 364,820.40

      A very curious trade:
      18:03:08 3.718 574,06 2,134,358.80
      .
      .
      17:00:23 1.239 2,334,225 2,892,104.78 -> after hours
      16:10:44 1,2400 7.927.000 -> Schlusskurs
      15:59:39 1,2000 9

      (http://www.smh.com.au/business/markets/quotes/course-of-sale…
      2 Antworten
      Avatar
      schrieb am 21.03.14 13:39:28
      Beitrag Nr. 512 ()
      Antwort auf Beitrag Nr.: 46.673.695 von Finee am 21.03.14 12:58:43Bitte anschnallen: Prana-Aktie vor dem Ausbruch!!!
      (IMHO)
      1 Antwort
      Avatar
      schrieb am 21.03.14 18:29:51
      Beitrag Nr. 513 ()
      Antwort auf Beitrag Nr.: 46.674.065 von Finee am 21.03.14 13:39:28Hoffen wir, in die richtige Richtung - nach oben!



      :rolleyes:
      Avatar
      schrieb am 21.03.14 18:30:23
      Beitrag Nr. 514 ()
      Heute übrigens dreifacher Hexensabbat an den Börsen...
      Avatar
      schrieb am 21.03.14 19:26:34
      Beitrag Nr. 515 ()
      Alzheimer-Forschung: Neue Ideen dringend gesucht

      21.03.2014

      Bislang sind alle Versuche gescheitert, Alzheimer zu heilen. Es kann sein, dass sie in die falsche Richtung gingen.


      http://www.faz.net/aktuell/wissen/medizin/alzheimer-forschun…




      :rolleyes:
      Avatar
      schrieb am 31.03.14 09:38:48
      Beitrag Nr. 516 ()
      Spannung steigt:

      Prana Biotechnology's (ASX: PBT, NASDAQ: PRAN) shares are in pre-open today, following the ASX granting the company a trading halt.

      The halt was granted pending results of its PBT2 IMAGINE Alzheimer’s Disease Phase II Trial.

      PBT's shares last traded at around $1, which is five times higher than a year ago.

      The halt will remain in place until the opening of trade on Wednesday 2nd April 2014, or earlier if an announcement was made to the market.
      Avatar
      schrieb am 31.03.14 12:37:50
      Beitrag Nr. 517 ()
      Schaut nicht so gut aus...

      http://www.nasdaq.com/symbol/pran/premarket
      Avatar
      schrieb am 31.03.14 13:18:10
      Beitrag Nr. 518 ()
      Leider ja ...

      Prana says drug fails Alzheimer's disease study

      http://www.reuters.com/article/2014/03/31/prana-alzheimers-i…
      Avatar
      schrieb am 01.04.14 09:42:09
      Beitrag Nr. 519 ()
      EINE WUNDERSCHÖNE KATASTROPHE, aber das ist kein Weltuntergang!
      Avatar
      schrieb am 01.04.14 12:12:34
      Beitrag Nr. 520 ()
      Forum: ASX - By Stock
      Code: PBT - PRANA BIOTECHNOLOGY LIMITED

      "Let's not spin it. The result is a shock, the trial failed. Let's not spin it because the people who got it right for all the wrong reasons appear to have won. Let's not spin it because we have lost our money or our profits.

      Let's be sad for the people with, and the carers of people with, degenerative neurological conditions who have had their short term hopes for a genuine modifier of these conditions dashed.

      Hopefully, it is not the end of PBT2 as a potential treatment, but the road ahead is now longer and harder. Let's hope that the curse of AD and other neurological conditions, has suffered an irrecoverable dent from the efforts of the scientists and believers involved in this project. Let's hope that this unexpected setback is not the end, but another beginning in the fight for an effective treatment.

      Most of all let's hope that these results are analysed objectively. It is no good flogging a dead horse, but neither is it prudent to throw out the baby with the bath water.

      It has been a pleasure to read and contribute to this forum. Good luck to all those who gave their time and researched fairly and objectively over the years - there is no blame there.

      This result is the nature of the scientific method which, hopefully, will prevail in the end.
      "
      Avatar
      schrieb am 01.04.14 17:10:13
      Beitrag Nr. 521 ()
      Twitter

      Dr. Rudy Tanzi ‏@RudyTanzi (vor 3 Std.)
      PBT2 misses primary endpoint in study of 40 Alzheimer's patients, but continues to be developed for Alzheimer's and Huntington's disease.
      1 Antwort
      Avatar
      schrieb am 01.04.14 18:46:07
      Beitrag Nr. 522 ()
      Antwort auf Beitrag Nr.: 46.746.781 von Finee am 01.04.14 17:10:13Traumtänzer Tanzi
      Avatar
      schrieb am 03.04.14 15:18:03
      Beitrag Nr. 523 ()
      Avatar
      schrieb am 18.04.14 09:16:56
      Beitrag Nr. 524 ()
      schade, war aber ein einkalkuliertes risiko... die krücken sind nu im arsch
      mal gut das mit 0,22 € der einstiegskurs nun nicht ganz so doll schmerzt.
      also kaufen schlafengehen und 10 jahre später mal schaun lol
      Avatar
      schrieb am 28.05.14 13:45:03
      Beitrag Nr. 525 ()
      Steht hier eine Übernahme an?

      Wenn man das US Board liest könnte es hier abgehen. Bin ich gespannt mit meinem Long Investment.

      Nur meine Meinung, keine Kauf- oder Verkaufsempfehlung.
      Avatar
      schrieb am 19.11.15 09:15:17
      Beitrag Nr. 526 ()
      12 November, 2015
      Dear Friends,
      I am writing this letter, first, to express my appreciation for your support of Prana Biotechnology and, more generally, drug development aimed at preventing and treating this terrible disease called Alzheimer’s disease (AD). Second, I would like to take the opportunity to update you on how recent studies modelling AD, using human stem cell-derived neurons grown in 3D cultures, have dramatically enhanced and clarified our understanding of the pathogenic events underlying AD-related neurodegeneration.
      The past year of AD research has arguably been one of the most exciting in the last two decades. I say this in references to new revelations coming out of genetic studies of AD, as well as the insights regarding the etiology and pathogenic events underlying AD, emerging from our new model of the disease dubbed “Alzheimer’s-in-a-Dish”. We have developed this new model of AD using human stem cell-derived neural cultures grown in petri dishes in a gel that resembles the milieu of the brain. This is referred to as 3-D neural culture and we used it to recreate for the first time, the two major pathological hallmarks of AD - deposits of beta-amyloid protein, which appear as senile plaques (outside neurons), and twisted aggregates of tau proteins that manifest as neurofibrillary tangles (inside neurons). While those in the AD research field agree that it is the tangles and inflammation that kill neurons, heavy debate has raged for thirty years in the Alzheimer’s research community as to what initiates the tangles and deadly neurodegenerative cascade—the beta-amyloid or something else.
      While our and other’s genetic studies of AD over the last three decades have strongly supported the notion that beta-amyloid acts as a trigger for tangle formation and neurodegeneration, evidence against this idea was suggested by two repeated findings. First, when the early-onset familial AD gene mutations in the amyloid precursor protein (APP), presenilin 1 (PSEN1) and presenilin 2 (PSEN2) were introduced into mice in attempts to create animal models for AD, plaques were observed, eventually leading to neuroinflammation, cell death, and cognitive deficits. However, no tangles were produced. This suggested beta-amyloid does not lead to tangles - at least, in mice. Second, many anti-amyloid therapies failed in clinical trials.
      Now, Alzheimer’s-in-a-dish, using human (not mouse) neurons, has clearly shown that beta-amyloid is sufficient to lead directly to tangles (after ~9 weeks in culture). Furthermore, we showed that if you stop the deposition of beta-amyloid, you also stop the tangles. Regarding the numerous failed clinical trials targeting beta-amyloid, we now know that beta-amyloid accumulates 10-20 years before any cognitive symptoms of AD and that treating AD by only targeting amyloid in mid-late stage patients is too little-too late. Beta-amyloid deposition must be targeted as early as possible, preferably at the pre-dementia stage of the disease process.
      Recent discoveries in AD genetics have also strongly implicated neuroinflammation as the third pillar of AD pathology (in addition to beta-amyloid deposition (e.g. as senile plaques and neurofibrillary tangles). In 2008, we discovered the new AD gene, CD33, and in 2012, Decode (Iceland) discovered the AD gene, TREM2. We now know that these two genes play a major role in controlling neuroinflammation in AD. These are now serving as drug targets for regulating neuroinflammation in AD. This is particularly important in patients with mid-late stage AD.
      The newest combined genetic, imaging, biomarker, and Alzheimer’s-in-a-Dish data now collectively illustrate a path for Alzheimer’s pathology in which first, beta-amyloid accumulates in the brain, decades before cognitive impairment. Beta-amyloid then triggers the production of tangles that kill neurons from within as well as neuro-inflammation, which kills more neurons. As increasing numbers of neurons die, there is more neuro-inflammation driven by microglial cells (regulated by the genes, CD33 and TREM2). Inflammation then drives even more plaques and tangles, and a vicious cycle ensues.
      We have been using Alzheimer’s-in-a-Dish to find drugs that will slow or halt plaque and tangle formation. Among those that are being tested is PBT2. Studies of PBT2 are still in progress and once confirmed, will be submitted for publication. So far, the preliminary findings show that PBT2 has the following effects in Alzheimer’s-in-a-Dish: 1. A trend in the direction of attenuation of the aggregation and fibrillization of the Abeta peptide into beta-amyloid, 2. significantly reduced tangle formation, and 3. significantly increased cell viability. Once these results are confirmed, PBT2 would become the only compound tested in Alzheimer’s-in-a-Dish to achieve all three of these effects on AD pathology.
      In closing, based on recent findings, I firmly believe, that beta-amyloid remains the best target for preventing and treating AD, but this must be achieved in the earliest stages of the disease process. Based on the combined data, I continue to believe that PBT2 carries great potential for curbing plaque and tangle formation, while also enhancing neuronal cell viability as an AD therapeutic.
      Sincerely yours,
      Rudolph E. Tanzi, Ph.D.

      http://www.conferencecalltranscripts.org/no/summary/?id=2179788
      Avatar
      schrieb am 29.12.20 17:42:56
      Beitrag Nr. 527 ()
      Ist hier noch/wieder jemand investiert? Nach diesen News bin ich eine kleine Position eingegangen. Wenn die Story ins laufen kommt dann hats hier grosses Potential:

      New commercial opportunity for PBT2
      Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”) has today announced it has been granted a licence by UniQuest, the commercialisation company of The University of Queensland (UQ), to novel zinc ionophore technology to combat antimicrobial resistance in superbugs.
      Under the licence, Alterity has secured the worldwide exclusive right to patented technology to develop and commercialise therapies that re-sensitise bacteria to antibiotics. The licensed technology combines Alterity’s PBT2 and other zinc ionophores with commonly used antibiotics to treat infections caused by multidrug resistant bacteria. This is an opportunity for Alterity to further leverage its investment in PBT2.
      PBT2, Alterity’s most advanced zinc ionophore, breaks the resistance of many important superbugs to available antibiotics, and is covered for this use by patents until 2038. Importantly, PBT2 has previously completed long term preclinical safety studies and phase 2 clinical trial testing in other indications and has been shown to have a favourable safety profile in those trials.
      A recently published article in the high-impact journal Science Translational Medicine1, showed that PBT2 could reverse antibiotic resistance to critical superbugs and demonstrate efficacy in an animal model of sepsis.
      Professor Mark Walker of The University of Queensland said: “The results from our paper demonstrate that by breaking the resistance of superbugs, PBT2 and other zinc ionophores have the potential to restore the efficacy of several widely available antibiotics.”
      The authors also noted that superbugs exposed to a combination of PBT2 and antibiotics had a very low propensity to develop further resistance, making the emergence of cross-resistance to the novel treatment unlikely. Thus, PBT2 may help address the issue of antimicrobial resistance without becoming part of the problem.
      Geoffrey Kempler, Alterity’s Chairman and CEO said: “Even without the effects Covid-19, antibiotic resistant pathogens kill more than 700,000 people each year and represent a major threat to global public health”.
      “The approach developed by our collaborators is novel and potentially revolutionary. Existing antibiotics are losing the battle against these infections and science is struggling to keep up as pathogens continually adapt. Because we can combine PBT2 with existing antibiotics, many of which are generic, this approach has strong commercial value to Alterity.”
      The World Health Organisation has declared antibiotic resistant bacteria a serious threat to global health that requires novel strategies to overcome the problem. PBT2 can break the resistance of the most important resistant pathogens designated by the WHO.1,2
      “The critical and urgent importance of this work is amplified in the current context of Covid-19, because secondary bacterial infections associated with viral pandemics are an important cause of mortality3. The need for effective antimicrobial regimens is very high,” added Mr Kempler.
      UniQuest CEO Dr Dean Moss said the technology had the potential to be a catalyst for change in what was a significant and growing public health problem. “This partnership has significant potential to help combat a growing and complex global problem,” he said.
      In exchange for the grant of exclusive worldwide rights, once Alterity generates commercialization revenue, UniQuest is entitled to receive certain payments including milestone and royalty payments commensurate with academic licenses.
      Alterity intends to direct new resources to the project with no impact on its lead commercialisation program for ATH434, which is advancing to Phase 2 in Multiple System Atrophy, a Parkinsonian disorder with no approved therapy.
      Alterity Therapeutics | 1,410 $
      Avatar
      schrieb am 01.07.21 14:38:34
      Beitrag Nr. 528 ()
      Vor 48 Minuten kam das hier:

      Alterity Therapeutics granted a new US patent targeting major neurodegenerative diseases including Alzheimer's and Parkinson's

      https://www.prnewswire.com/news-releases/alterity-therapeuti…
      Alterity Therapeutics | 1,765 €
      3 Antworten
      Avatar
      schrieb am 08.07.21 09:03:59
      Beitrag Nr. 529 ()
      Antwort auf Beitrag Nr.: 68.662.909 von Malecon am 01.07.21 14:38:34Nach der Nachricht hat sich erstmal nicht viel bewegt. Aber gestern Afterhours dann 12 % plus. Kurzzeitig sogar an der 2 $ Marke gekratzt.
      Könnte heute interessant werden.
      Alterity Therapeutics | 1,550 
      2 Antworten
      Avatar
      schrieb am 08.07.21 11:04:50
      Beitrag Nr. 530 ()
      Antwort auf Beitrag Nr.: 68.718.314 von SirTobi678 am 08.07.21 09:03:59Premarket rennt gerade davon. 1,98 USD!! :eek:
      Alterity Therapeutics | 1,490 
      1 Antwort
      Avatar
      schrieb am 08.07.21 22:28:15
      Beitrag Nr. 531 ()
      Antwort auf Beitrag Nr.: 68.720.357 von SirTobi678 am 08.07.21 11:04:50Also ich muss schon sagen, bei stocktwits sind die immer ganz gut an so Werten dran, die kurzzeitig gut laufen. Hier und bei Dare Biosience
      kann ich wohl morgen paar Gewinne einsacken. Exela war auch ein heißer Ritt, habe zum Glück heute früh genug den Einsatz rausgenommen.
      Alterity Therapeutics | 1,680 
      • 2
       Durchsuchen


      Beitrag zu dieser Diskussion schreiben


      Zu dieser Diskussion können keine Beiträge mehr verfasst werden, da der letzte Beitrag vor mehr als zwei Jahren verfasst wurde und die Diskussion daraufhin archiviert wurde.
      Bitte wenden Sie sich an feedback@wallstreet-online.de und erfragen Sie die Reaktivierung der Diskussion oder starten Sie
      hier
      eine neue Diskussion.

      Investoren beobachten auch:

      WertpapierPerf. %
      -2,22
      -0,07
      -0,72
      -0,17
      -0,18
      -8,81
      +0,06
      -0,98
      +0,34
      +0,12
      Prana Biotech: PBT-2